

# Cristiana Catena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/18905/publications.pdf>

Version: 2024-02-01

116  
papers

4,811  
citations

136940

32  
h-index

102480

66  
g-index

117  
all docs

117  
docs citations

117  
times ranked

4311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	11.4	595
2	Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment. <i>Archives of Internal Medicine</i> , 2008, 168, 80.	3.8	476
3	Long-term Renal Outcomes in Patients With Primary Aldosteronism. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2638-45.	7.4	328
4	Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2007, 50, 911-918.	2.7	312
5	Insulin Sensitivity in Patients with Primary Aldosteronism: A Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3457-3463.	3.6	232
6	Cellular mechanisms of insulin resistance in rats with Fructose-Induced hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 973-978.	2.0	137
7	Insulin Resistance and Hyperinsulinemia Are Related to Plasma Aldosterone Levels in Hypertensive Patients. <i>Diabetes Care</i> , 2007, 30, 2349-2354.	8.6	136
8	Intrarenal Hemodynamics in Primary Aldosteronism before and after Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1191-1197.	3.6	118
9	Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment. <i>American Journal of Hypertension</i> , 2010, 23, 1253-1260.	2.0	98
10	Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. <i>Journal of Hypertension</i> , 2013, 31, 3-15.	0.5	96
11	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 641-649.	2.7	94
12	Relationships of Plasma Renin Levels with Renal Function in Patients with Primary Aldosteronism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 722-731.	4.5	92
13	Insulin receptors and renal sodium handling in hypertensive fructose-fed rats. <i>Kidney International</i> , 2003, 64, 2163-2171.	5.2	86
14	Relationship of Fibrinogen Levels and Hemostatic Abnormalities With Organ Damage in Hypertension. <i>Hypertension</i> , 2000, 36, 978-985.	2.7	77
15	Abnormalities of Glucose Metabolism in Patients With Early Renal Failure. <i>Diabetes</i> , 2002, 51, 1226-1232.	0.6	75
16	Elevated Homocysteine Levels Are Associated With the Metabolic Syndrome and Cardiovascular Events in Hypertensive Patients. <i>American Journal of Hypertension</i> , 2015, 28, 943-950.	2.0	74
17	Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. <i>American Journal of Medicine</i> , 2000, 109, 556-561.	1.5	62
18	Relationship of Plasma Renin With a Prothrombotic State in Hypertension: Relevance for Organ Damage. <i>American Journal of Hypertension</i> , 2008, 21, 1347-1353.	2.0	61

#	ARTICLE	IF	CITATIONS
19	Mineralocorticoid Antagonists Treatment Versus Surgery in Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2010, 42, 440-445.	1.5	56
20	Adrenalectomy Is Comparable With Medical Treatment for Reduction of Left Ventricular Mass in Primary Aldosteronism: Meta-Analysis of Long-Term Studies. <i>American Journal of Hypertension</i> , 2015, 28, 312-318.	2.0	56
21	Aldosterone and the Heart: From Basic Research to Clinical Evidence. <i>Hormone and Metabolic Research</i> , 2012, 44, 181-187.	1.5	54
22	Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. <i>Kidney International</i> , 1999, 56, 1049-1057.	5.2	51
23	New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). <i>Journal of Hypertension</i> , 2005, 23, 1617-1631.	0.5	50
24	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. <i>Molecular and Cellular Endocrinology</i> , 2014, 394, 13-20.	3.2	48
25	Abnormalities of Insulin Receptors in Spontaneously Hypertensive Rats. <i>Hypertension</i> , 1996, 27, 955-961.	2.7	47
26	Serum lipoprotein(a) concentrations and alcohol consumption in hypertension. <i>Journal of Hypertension</i> , 2003, 21, 281-288.	0.5	45
27	Oxidative Stress Is Activated by Free Fatty Acids in Cultured Human Hepatocytes. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 397-401.	1.3	43
28	Alcohol-Induced Endothelial Changes Are Associated With Oxidative Stress and Are Rapidly Reversed After Withdrawal. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 1889-1898.	2.4	41
29	Nonalcoholic Fatty Liver Disease in Primary Aldosteronism: A Pilot Study. <i>American Journal of Hypertension</i> , 2010, 23, 2-5.	2.0	41
30	Aldosterone and Left Ventricular Remodeling. <i>Hormone and Metabolic Research</i> , 2015, 47, 981-986.	1.5	41
31	Increased Fibrinogen Levels and Hemostatic Abnormalities in Patients with Arteriolar Nephrosclerosis: Association with Cardiovascular Events. <i>Thrombosis and Haemostasis</i> , 2000, 84, 565-570.	3.4	35
32	Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2007, 2, 13-21.	1.5	35
33	Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. <i>Journal of Hypertension</i> , 2008, 26, 2191-2197.	0.5	34
34	The SPARTACUS Trial: Controversies and Unresolved Issues. <i>Hormone and Metabolic Research</i> , 2017, 49, 936-942.	1.5	33
35	Predictive Factors of Left Ventricular Mass Changes after Treatment of Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2012, 44, 188-193.	1.5	32
36	Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 167-175.	2.3	32

#	ARTICLE	IF	CITATIONS
37	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171.	3.4	32
38	Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Na <sup>+</sup> -ve Patients With Hypertension. <i>Hypertension</i> , 2015, 65, 1231-1237.	2.7	31
39	Dietary Salt Intake Is a Determinant of Cardiac Changes After Treatment of Primary Aldosteronism. <i>Hypertension</i> , 2016, 68, 204-212.	2.7	31
40	Echocardiographic Comparison of COVID-19 Patients with or without Prior Biochemical Evidence of Cardiac Injury after Recovery. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 193-195.	2.8	31
41	Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment. <i>Journal of Hypertension</i> , 2007, 25, 1443-1450.	0.5	30
42	Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge. <i>Clinical Research in Cardiology</i> , 2021, 110, 1063-1072.	3.3	28
43	Involvement of endothelium-dependent and -independent mechanisms in midazolam-induced vasodilation. <i>Hypertension Research</i> , 2011, 34, 929-934.	2.7	27
44	Aldosterone, organ damage and dietary salt. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 922-928.	1.9	25
45	Treatment of Primary Aldosteronism and Organ Protection. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	1.5	25
46	Moderate Alcohol Consumption Is Associated With Left Ventricular Diastolic Dysfunction in Nonalcoholic Hypertensive Patients. <i>Hypertension</i> , 2016, 68, 1208-1216.	2.7	25
47	Plasma Glucose Levels and Left Ventricular Diastolic Function in Nondiabetic Hypertensive Patients. <i>American Journal of Hypertension</i> , 2013, 26, 1353-1361.	2.0	21
48	Glucose Metabolism and Insulin Receptor Binding and mRNA Levels in Tissues of Dahl Hypertensive Rats. <i>American Journal of Hypertension</i> , 1997, 10, 1223-1230.	2.0	20
49	Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 289-292.	3.6	20
50	Association of Aldosterone With Left Ventricular Mass in Hypertension: Interaction With Plasma Fibrinogen Levels. <i>American Journal of Hypertension</i> , 2013, 26, 111-117.	2.0	19
51	Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?. <i>Hormone and Metabolic Research</i> , 2015, 47, 1000-1006.	1.5	19
52	Fish Meal Supplementation and Ambulatory Blood Pressure in Patients With Hypertension: Relevance of Baseline Membrane Fatty Acid Composition. <i>American Journal of Hypertension</i> , 2014, 27, 471-481.	2.0	18
53	Uricaemia and left ventricular mass in hypertensive patients. <i>European Journal of Clinical Investigation</i> , 2014, 44, 972-981.	3.4	18
54	A Prothrombotic State is Associated with Early Arterial Damage in Hypertensive Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 471-478.	2.0	17

#	ARTICLE	IF	CITATIONS
55	Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism. <i>Journal of Hypertension</i> , 2016, 34, 1778-1786.	0.5	17
56	Association of a prothrombotic state with left-ventricular diastolic dysfunction in hypertension. <i>Journal of Hypertension</i> , 2013, 31, 2077-2084.	0.5	16
57	Lipoprotein (a), haemostatic variables and cardiovascular damage in hypertensive patients. <i>Journal of Hypertension</i> , 2000, 18, 709-716.	0.5	15
58	Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. <i>European Journal of Endocrinology</i> , 2013, 168, C1-C5.	3.7	15
59	Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1439-1446.	3.4	15
60	Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1034-1042.	2.3	15
61	Effects of the Consumption of Fish Meals on the Carotid IntimaMedia Thickness in Patients with Hypertension: A Prospective Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 941-956.	2.0	14
62	Aldosterone and the Heart: Still an Unresolved Issue?. <i>Frontiers in Endocrinology</i> , 2014, 5, 168.	3.5	14
63	Plasma parathyroid hormone and cardiovascular disease in treatment-naïve patients with primary hyperparathyroidism: The EPATH trial. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1173-1180.	2.0	14
64	Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. <i>World Journal of Gastroenterology</i> , 2019, 25, 6094-6106.	3.3	14
65	Hypertension and Abnormalities of Carbohydrate Metabolism Possible Role of the Sympathetic Nervous System. <i>American Journal of Hypertension</i> , 1997, 10, 678-682.	2.0	13
66	Effects of Antihypertensive Drugs on Alcohol-Induced Functional Responses of Cultured Human Endothelial Cells. <i>Hypertension Research</i> , 2008, 31, 345-351.	2.7	13
67	Carotid artery stiffness is related to hyperinsulinemia and insulin-resistance in middle-aged, non-diabetic hypertensive patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 968-974.	2.6	12
68	Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. <i>American Journal of Cardiovascular Disease</i> , 2012, 2, 50-7.	0.5	12
69	The Dual Role of the Kidney in Primary Aldosteronism: Key Determinant in Rescue From Volume Expansion and Persistence of Hypertension. <i>American Journal of Kidney Diseases</i> , 2009, 54, 594-597.	1.9	11
70	Plasma Lipoprotein(a) Levels and Atherosclerotic Renal Artery Stenosis in Hypertensive Patients. <i>Kidney and Blood Pressure Research</i> , 2015, 40, 166-175.	2.0	10
71	Salt, Aldosterone, and Parathyroid Hormone: What Is the Relevance for Organ Damage?. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-8.	1.5	10
72	Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. <i>PLoS ONE</i> , 2017, 12, e0173799.	2.5	10

#	ARTICLE	IF	CITATIONS
73	Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data. <i>Hormone and Metabolic Research</i> , 2018, 50, 375-382.	1.5	10
74	Prognostic Role of Malnutrition Diagnosed by Bioelectrical Impedance Vector Analysis in Older Adults Hospitalized with COVID-19 Pneumonia: A Prospective Study. <i>Nutrients</i> , 2021, 13, 4085.	4.1	10
75	Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 33-37.	2.2	9
76	The vascular response to vasodilators is related to the membrane content of polyunsaturated fatty acids in hypertensive patients. <i>Journal of Hypertension</i> , 2015, 33, 993-1000.	0.5	9
77	Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 774-783.	2.0	9
78	Plasma Lipoprotein(a) Levels as Determinants of Arterial Stiffening in Hypertension. <i>Biomedicines</i> , 2021, 9, 1510.	3.2	9
79	Hyperaldosteronism and Left Ventricular Hypertrophy. <i>Hypertension</i> , 2010, 56, e26; author reply e27.	2.7	8
80	Intrarenal Vascular Resistance is Associated With a Prothrombotic State in Hypertensive Patients. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 929-936.	2.0	8
81	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism – The randomized, placebo-controlled EPATH trial. <i>Bone</i> , 2017, 105, 212-217.	2.9	8
82	Microalbuminuria and plasma aldosterone levels in nondiabetic treatment-naïve patients with hypertension. <i>Journal of Hypertension</i> , 2017, 35, 2510-2516.	0.5	8
83	Early renal failure as a cardiovascular disease: Focus on lipoprotein(a) and prothrombotic state. <i>World Journal of Nephrology</i> , 2015, 4, 374.	2.0	8
84	Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study. <i>Journal of Clinical Hypertension</i> , 2016, 18, 543-550.	2.0	7
85	Benzodiazepines: An Old Class of New Antihypertensive Drugs?. <i>American Journal of Hypertension</i> , 2018, 31, 402-404.	2.0	7
86	The Pivotal Role of Oleuropein in the Anti-Diabetic Action of the Mediterranean Diet: A Concise Review. <i>Pharmaceutics</i> , 2022, 14, 40.	4.5	7
87	Elevated Intrarenal Resistive Index Predicted Faster Renal Function Decline and Long-Term Mortality in Non-Proteinuric Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 2995.	2.4	7
88	Association of Post-Saline Load Plasma Aldosterone Levels With Left Ventricular Hypertrophy in Primary Hypertension. <i>American Journal of Hypertension</i> , 2016, 29, 303-310.	2.0	6
89	The Metabolic Syndrome and the Membrane Content of Polyunsaturated Fatty Acids in Hypertensive Patients. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 343-351.	1.3	6
90	Aldosterone-to-Renin Ratio Is Associated With Reduced 24-Hour Heart Rate Variability and QTc Prolongation in Hypertensive Patients. <i>Medicine (United States)</i> , 2016, 95, e2794.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Pre-Procedural Statin Use Is Associated with Improved Long-Term Survival and Reduced Major Cardiovascular Events in Patients Undergoing Carotid Artery Stenting: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2018, 7, 286.	2.4	6
92	Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension. <i>Hypertension</i> , 2022, 79, 1435-1444.	2.7	6
93	Renal Function in Primary Aldosteronism. <i>Hypertension</i> , 2006, 48, e110; author reply e111.	2.7	5
94	The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-2.	1.5	5
95	Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 135-142.	2.2	4
96	Atrial fibrillation and its complications in arterial hypertension: The potential preventive role of ω-3 polyunsaturated fatty acids. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 1937-1948.	10.3	4
97	Interactions between vitamin D levels, cardiovascular risk factors, and atherothrombosis markers in patients with symptomatic peripheral artery disease. <i>Vascular Medicine</i> , 2021, 26, 315-316.	1.5	4
98	Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension. <i>Nutrients</i> , 2022, 14, 311.	4.1	4
99	Prognostic scores and early management of septic patients in the emergency department of a secondary hospital: results of a retrospective study. <i>BMC Emergency Medicine</i> , 2021, 21, 152.	1.9	4
100	Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	4
101	Metabolic Dysfunction in Primary Aldosteronism. <i>Hypertension</i> , 2009, 53, e37; author reply e38.	2.7	3
102	Omega-3 Polyunsaturated Fatty Acids in Blood Pressure Control and Essential Hypertension. , 0, , .		3
103	Decreased fibrinolytic activity is associated with carotid artery stiffening in arterial hypertension. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 57.	0.9	3
104	Arterial stiffening in hypertension: is it just high blood pressure?. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 1073.	1.4	3
105	Glucose Metabolism In Early Renal Failure. <i>American Journal of Kidney Diseases</i> , 2005, 46, 367.	1.9	2
106	Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 1017.	2.0	2
107	Salt, Hypertension, and Cardiovascular Disease. <i>Journal of Clinical and Laboratory Investigation Updates</i> , 2014, 2, 46-49.	0.4	2
108	Kidney in primary aldosteronism: A key determinant of treatment outcome. <i>World Journal of Hypertension</i> , 2012, 2, 1.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Response to "Plasma Homocysteine Levels and Endothelial Dysfunction in Cerebro- and Cardiovascular Diseases in the Metabolic Syndrome" American Journal of Hypertension, 2015, 28, 1490-1490.	2.0	1
110	Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. Journal of Hypertension, 2021, 39, 864-866.	0.5	1
111	Secondary hyperparathyroidism is associated with postpartum blood pressure in preeclamptic women and normal pregnancies. Journal of Hypertension, 2021, 39, 563-572.	0.5	1
112	The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension. Current Hypertension Reviews, 2005, 1, 189-200.	0.9	0
113	Potassium-Sparing Diuretics in Hypertension. , 2012, , .		0
114	Editorial Comment from <i>D</i> <i>C</i> atena, <i>D</i> <i>C</i> olussi and <i>D</i> <i>S</i> chi to Preoperative masked renal damage in <i>J</i> apanese patients with primary aldosteronism: Identification of predictors for chronic kidney disease manifested after adrenalectomy. International Journal of Urology, 2013, 20, 692-693.	1.0	0
115	The Rising Burden of Hypertensive Renal Disease in Low-Income Countries: Is it Time to Take Action?. Journal of Clinical Hypertension, 2016, 18, 405-407.	2.0	0
116	Elevated Blood Pressure in Children of Cardiovascular Risk Mothers: Could Maternal Folic Acid Be the Link?. American Journal of Hypertension, 2017, 30, 473-475.	2.0	0